Skip to main content
Mantapex
Will the FDA approve intismeran autogene (V940/mRNA-4157)?
intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanomaScience
Kalshi Active 5 markets·92¢ Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028?·$0 Total Volume·-- Liquidity·-- OI
6mo·Apr 8, 2027

Track your prediction positions

Connect your Kalshi account to track your contracts, P&L, and settlements.

Wide spread
No chart data available

Markets

5
(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Jan 2028
$0 vol
92% ▲0.0%
(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Apr 2027
$0 vol
50% --
(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Jul 2027
$0 vol
50% ▲0.0%
(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Oct 2027
$0 vol
50% ▲0.0%
(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Jul 2028
$0 vol
50% --
(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Jan 2028
No order book data available

If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Apr 1, 2027, then the market resolves to Yes.

Series

KXFDAAPPROVE
View Full Series

Track Your Bets on Kalshi — and Everything Else

Create a free portfolio starting with your Kalshi positions, P&L & live odds. Then add crypto wallets, exchanges, DeFi & more — all in one place.

Polymarket
Kalshi
50+ Chains
40+ Exchanges
DeFi
NFTs
16K+ Tokens
100% free· Read-only· Encrypted